GeoVax Labs initiated with a Buy at EF Hutton

EF Hutton initiated coverage of GeoVax Labs with a Buy rating and $18 price target. GeoVax’s COVID-19 vaccine for immunocompromised patients was recently selected by the Biomedical Advanced Research and Development Authority for Project Nextgen, the analyst tells investors in a research note. The firm says the company stands to receive an award of $350M plus to conduct a Phase 2b trial of the vaccine. GeoVax has transformed itself under the leadership of David Dodd, emerging with two assets “that are worthy of attention,” according to EF.